A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy

M J Clemons, E Marshall, J Dürig, K Watanabe, A Howell, David Miles, Helena Earl, Julie Kiernan, Audrey Griffiths, K Towlson, P DeTakats, Nydia G. Testa, M Dougal, Michael G Hunter, L Michael Wood, Lloyd G Czaplewski, Andrew J. Millar, T. Michael Dexter, Brian I. Lord

Research output: Contribution to journalArticlepeer-review


BB-10010 is a variant of the human form of macrophage inflammatory protein-1alpha (MIP-1alpha), which has been shown in mice to block the entry of hematopoietic stem cells into S-phase and to increase their self-renewal capacity during recovery from cytotoxic damage. Its use may constitute a novel approach for protecting the quality of the stem cell population and its capacity to regenerate after periods of cytotoxic treatment. Thirty patients with locally advanced or metastatic breast cancer were entered into the first randomized, parallel group controlled phase II study. This was designed to evaluate the potential myeloprotective effects of a 7-day regimen of BB-10010 administered to patients receiving six cycles of 5-fluorouracil (5-FU), adriamycin, and cyclophosphamide (FAC) chemotherapy. Patients were randomized, 10 receiving 100 microgram/kg BB-10010, 11 receiving 30 microgram/kg BB-10010, and nine control patients receiving no BB-10010. BB-10010 was well-tolerated in all patients with no severe adverse events related to the drug. Episodes of febrile neutropenia complicated only 4% of the treatment cycles and there was no difference in incidence between the treated and nontreated groups. Studies to assess the generation of progenitor cells in long-term bone marrow cultures were performed immediately preceding chemotherapy and at the end of six dosing cycles in 18 patients. Circulating neutrophils, platelets, CD 34(+) cells, and granulocyte/macrophage colony-forming cell (GM-CFC) levels were determined at serial time points in cycles 1, 3, and 6. The results showed similar hemoglobin and platelet kinetics in all three groups. On completion of the six treatment cycles, the average pretreatment neutrophil levels were reduced from 5.3 to 1.7 x 10(9)/L in the control patients and from 4.3 to 1.9 and 4.5 to 2.5 x 10(9)/L in the 30/100 microgram/kg BB-10010 groups, respectively. Relative to their pretreatment values, 50% of the patients receiving BB-10010 completed the treatment with neutrophil values significantly higher than any of the controls (P = .02). Mobilization of GM-CFC was enhanced by BB-10010 with an additional fivefold increase over that generated by chemotherapy alone, giving a maximal 25-fold increase over pretreatment values. Bone marrow progenitor assays before and after this standard regimen of chemotherapy indicated little long-term cumulative impairment to recovery from chemotherapy. Despite the limited cumulative damage to the bone marrow, which may have minimized the protective value of BB-10010 during this regimen of chemotherapy, better recovery of neutrophils in the later treatment cycles with BB-10010 was indicated in a number of patients.

Original languageEnglish
Pages (from-to)1532-40
Number of pages9
Issue number5
Publication statusPublished - 1 Sept 1998


  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Marrow Cells
  • Breast Neoplasms
  • Cell Count
  • Cells, Cultured
  • Chemokine CCL3
  • Chemokine CCL4
  • Cyclophosphamide
  • Doxorubicin
  • Female
  • Fluorouracil
  • Hematopoiesis
  • Hematopoietic Stem Cells
  • Humans
  • Leukocyte Count
  • Macrophage Inflammatory Proteins
  • Middle Aged
  • Neoplasm Metastasis
  • Neutrophils
  • Clinical Trial
  • Clinical Trial, Phase II
  • Journal Article
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't


Dive into the research topics of 'A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy'. Together they form a unique fingerprint.

Cite this